Thursday, October 14, 2021 8:08:56 AM
Else Nutrition Successfully Completes First Production Trial Run of its Novel, Plant-Based Infant Formula
Development brings Company a step closer to bringing first-of-its-kind product to $90 Billion Global Infant Formula Market
VANCOUVER, British Columbia, Oct. 13, 2021 (GLOBE NEWSWIRE) -- ELSE NUTRITION HOLDINGS INC. (BABY.V) (BABYF) (0YL.F) ("Else" or the "Company") the Plant-Based baby, toddler and children nutrition company, today announced that is has successfully completed its first commercial trial run of its patented, Plant-Based Infant Formula for age 0 -12 months as the Company continues its path for regulatory approval.
The trial run, which took place this week in the U.S., leveraged a global, first-of-its-kind technological development with one of the raw ingredients in the Plant-Based formulation. This patented processing method results in a cleaner ingredient, while keeping the nutritional value fully intact.
“This successful trial is a major step for the Company, as we move forward to provide real choice when it comes to dairy-free infant formula,” said Hamutal Yitzhak, CEO & Co-Founder of Else Nutrition. “The $90 billion global infant formula market has been dominated by dairy and soy for too long. This development brings us one step closer to commercializing a minimally processed, Plant-Based option to millions of wanting families globally,” she added.
About Else Nutrition Holdings Inc.
Development brings Company a step closer to bringing first-of-its-kind product to $90 Billion Global Infant Formula Market
VANCOUVER, British Columbia, Oct. 13, 2021 (GLOBE NEWSWIRE) -- ELSE NUTRITION HOLDINGS INC. (BABY.V) (BABYF) (0YL.F) ("Else" or the "Company") the Plant-Based baby, toddler and children nutrition company, today announced that is has successfully completed its first commercial trial run of its patented, Plant-Based Infant Formula for age 0 -12 months as the Company continues its path for regulatory approval.
The trial run, which took place this week in the U.S., leveraged a global, first-of-its-kind technological development with one of the raw ingredients in the Plant-Based formulation. This patented processing method results in a cleaner ingredient, while keeping the nutritional value fully intact.
“This successful trial is a major step for the Company, as we move forward to provide real choice when it comes to dairy-free infant formula,” said Hamutal Yitzhak, CEO & Co-Founder of Else Nutrition. “The $90 billion global infant formula market has been dominated by dairy and soy for too long. This development brings us one step closer to commercializing a minimally processed, Plant-Based option to millions of wanting families globally,” she added.
About Else Nutrition Holdings Inc.
Recent BABYF News
- Else Nutrition Expected to Benefit from FDA Regulatory Progress on Infant Formula Protein Standards • PR Newswire (US) • 03/10/2026 11:00:00 AM
- Micro Cap Surges on Major Retail Breakthrough • AllPennyStocks.com • 05/27/2025 03:52:00 PM
